|
Nov 2
|
BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update
|
|
Aug 23
|
BioCryst to Present at Upcoming Investor Conferences
|
|
Jul 20
|
Wall Street Analysts Think BioCryst (BCRX) Could Surge 107.2%: Read This Before Placing a Bet
|
|
Jul 20
|
BioCryst to Report Second Quarter 2023 Financial Results on August 3
|
|
Jul 19
|
BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in Turkey
|
|
Jul 18
|
Investing in BioCryst Pharmaceuticals (NASDAQ:BCRX) three years ago would have delivered you a 40% gain
|
|
Jul 17
|
BioCryst to Participate in the 2023 US HAEA National Summit
|
|
Feb 7
|
BioCryst to Report Fourth Quarter 2022 Financial Results on February 21
|
|
Feb 6
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Feb 3
|
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
|